イミダゾールプロピオネートは動脈硬化症の誘発因子であり,治療標的である

Annalaura Mastrangelo¹, Iñaki Robles-Vera¹, Diego Mañanes^1,2

¹Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.

Nature

|July 16, 2025

まとめ

微生物の代謝物質であるイミダゾールプロピオネート (ImP) は,動脈硬化症の程度と関連しています. ImP-イミダゾリン-1受容体 (I1R) 軸を標的にすることで,心血管疾患の新たな診断と治療戦略が提供される可能性があります.

科学分野:

心血管研究
免疫学
微生物群の研究

背景:

心血管疾患の主な原因である動脈硬化症は早期発見の改善方法が必要です
伝統的なリスクファクターの特定は早期の血管疾患に敏感な個体を見逃します
効果的な動脈硬化症の診断と治療には新しいバイオマーカーと治療目標が必要です

研究の目的:

動脈硬化症の発達におけるイミダゾールプロピオネート (ImP) の役割を調査する.
ImP誘発性動脈硬化の原因となる分子メカニズムを特定する.
ImP-イミダゾリン-1受容体 (I1R) 軸を潜在的な治療標的として調査する.

主な方法:

マウスモデルとヒトコホートにおける動脈硬化症の範囲とImPレベルとの関連性研究.
ImP投与によってマウスの動脈硬化症の誘導.
ImP暴露後の免疫反応と炎症反応の調査
骨髄細胞における ImP- I1R軸の阻害を伴う機能研究

主要な成果:

ImPレベルは,マウスとヒトの動脈硬化症の程度と相関しています.
ImPの投与は,脂質プロファイルの変化とは無関係に動脈硬化を引き起こす.
ImPは全身的および局所的な免疫および炎症反応を活性化します.
骨髄細胞における ImP- I1R軸は,ImP誘発性動脈硬化を媒介する.
ImP- I1R軸を遮断すると,動脈硬化症の発生を防ぐ.

結論:

ImPは活発な動脈硬化に関連した重要な要因です.
骨髄細胞における ImP- I1R信号経路は,動脈硬化症の進行に寄与する.
ImP-I1R軸は,早期動脈硬化症の診断とパーソナライズされた治療のための有望なターゲットです.

さらに関連する動画

09:14

The Rabbit Model of Accelerated Atherosclerosis: A Methodological Perspective of the Iliac Artery Balloon Injury

Published on: October 3, 2017

12.2K

07:36

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Published on: September 26, 2018

10.2K

関連する概念動画

01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

651

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

651

01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...

01:26

Targets for Drug Action: Overview

7.5K

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

7.5K

01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

702

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...

702

01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

878

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

878

関連する実験動画